ARRANON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Arranon, and when can generic versions of Arranon launch?
Arranon is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in ARRANON is nelarabine. There are two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the nelarabine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Arranon
A generic version of ARRANON was approved as nelarabine by ZYDUS PHARMS on November 17th, 2021.
US Patents and Regulatory Information for ARRANON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | ARRANON | nelarabine | INJECTABLE;INTRAVENOUS | 021877-001 | Oct 28, 2005 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ARRANON
See the table below for patents covering ARRANON around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 142636 | ⤷ Start Trial | |
| Australia | 1671888 | ⤷ Start Trial | |
| Australia | 622403 | ⤷ Start Trial | |
| Canada | 1330990 | COMPOSES ANTIVIRAUX (ANTIVIRAL COMPOUNDS) | ⤷ Start Trial |
| China | 1020107 | ⤷ Start Trial | |
| China | 1031233 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ARRANON
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0294114 | C00294114/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: NELARABIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57899 08.08.2007 |
| 0294114 | 07C0058 | France | ⤷ Start Trial | PRODUCT NAME: NELARABINE, OU L?UN DE SES DERIVES PHYSIOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/07/403/001 DU 20070822; REGISTRATION NO/DATE AT EEC: EU/1/07/403/001 DU 20070822 |
| 0294114 | SPC/GB08/006 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: NELARABINE, OR ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ETHERS, ESTERS, OR SALTS OF SUCH ESTERS THEREOF.; REGISTERED: UK EU/1/07/403/001 20070822 |
| 0294114 | C300302 | Netherlands | ⤷ Start Trial | PRODUCT NAME: NELARABINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR BAAR ZOUT, ETHER OF ESTER; REGISTRATION NO/DATE: EU/1/07/403/001 20070822 |
| 0294114 | 2007C/063 | Belgium | ⤷ Start Trial | PRODUCT NAME: NELARABINE; REGISTRATION NO/DATE: EU/1/07/403/001 20070823 |
| 0294114 | 300302 | Netherlands | ⤷ Start Trial | 300302, 20080527, EXPIRES: 20130526 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch